How well is your CDMO partnership working? Are you receiving the support you need from process development through to fill & finish? At ReciBioPharm, we go beyond collaboration – we stand alongside you throughout the entire journey, ensuring success from development to the delivery of the final drug product. What sets us apart is our integrated Advanced Therapies experience, enabling us to kickstart your fill and finish process, getting your life-changing therapies to patients rapidly. Fill and finish is the most critical step in the manufacturing of your ATMP. You can trust ReciBioPharm to drive your entire manufacturing journey, providing seamless support from start to finish. Read more: https://lnkd.in/gqw4bVtx #ATMP #RNA #CDMO #ManufacturingExcellence #LifeSciences
Recipharm
Tillverkning av läkemedel
Stockholm, Stockholm County 81 675 följare
Your innovation, delivered with certainty.
Om oss
Recipharm is an experienced, global CDMO dedicated to meeting pharmaceutical companies’ evolving needs through operational excellence, scientific know-how and customer connectivity. Headquartered in Stockholm, Sweden, we operate development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and are continuing to grow and expand our offering. Our worldwide reach paired with in-depth, localised market knowledge allows us to anticipate our customers’ needs and strengthen the support we provide to forge a healthier, more expansive and more fruitful future together. With a workforce of approximately 9,000 people, we are focused on supporting pharmaceutical companies with our full-service offering, taking products from early development through to commercial production. For over 25 years we’ve supported our customers throughout the entire product lifecycle, providing pharmaceutical expertise and managing complexity, time and time again to ensure their products are delivered with certainty.
- Webbplats
-
http://www.recipharm.com
Extern länk för Recipharm
- Bransch
- Tillverkning av läkemedel
- Företagsstorlek
- 5 001–10 000 anställda
- Huvudkontor
- Stockholm, Grafschaft Stockholm
- Typ
- Privatägt företag
- Specialistområden
- Pharmaceutical contract development and manufacturing, Commercial manufacturing, Analytical chemistry, Drug substance och Drug product development
Adresser
Anställda på Recipharm
Uppdateringar
-
EVENT | We are pleased to announce that our expert Vincenza Pironti, Ph.D., MBA , Head of Business Development, is speaking at PDA in Japan on September 10th. Vincenza will share insights on how predictive modelling can optimise the manufacturing process, reduce waste, and increase the likelihood of success in practical trials, while also explaining how a CDMO can assist pharma partners in anticipating and defining key factors such as Target Product Profile affordability, critical quality attributes, and accurate dosing in cartridge-based drug delivery systems. Learn more here: https://lnkd.in/gwp5UWKR #PDA #PFS #CDMO
-
We're ready to meet your sterile fill and finish needs, now and in the future! With a global footprint and specialist infrastructure, we support pharmaceutical companies worldwide. Our local experts offer tailored regulatory guidance for all target markets. Backed by a strong regulatory track record, our state-of-the-art facilities ensure seamless filling, tech transfer, and the supply of varied and continuously growing doses. Whether for small or large molecules, including vaccines, our global network and local experts are here to solve your fill and finish challenges. Learn more about our Sterile fill & Finish offering here: https://lnkd.in/dTWJ7aAx #CDMO #Fillfinish #Vaccine #PFS
-
To protect the efficacy of your drug and the safety of patients, testing for extractables and leachables (E&L) is critical. Recipharm’s extensive capabilities in E&L testing allow us to identify a wide range of additives and impurities that may have migrated from packaging to your drug product to ensure it meets regulatory standards. Download the fact sheet below to learn more: https://lnkd.in/eDd9rsZk #OSD #CDMO
-
-
The RNA therapeutic space is rapidly evolving, presenting unique opportunities for manufacturers. Continuous manufacturing offers significant advantages over traditional batch manufacturing, including: ● Reduced costs ● Faster production times ● Improved product quality Read the recent BioPharma-Reporter Q&A with Edita B., ReciBioPharm’s Head of Process Analytical Technology, Analytics Engineering & Data Science, to learn how process analytic technologies enable continuous RNA manufacturing and help manufacturers reduce risk and costs and improve quality. Read more: https://lnkd.in/dTZBdV9g #Biologics #RNAmanufacturing #Biopharma
-
-
✨ Heading to CPHI Milan? ✨ Don't miss exclusive tours of our state-of-the-art facilities in Masate and Pianezza! Register today: https://lnkd.in/d-qkrD3S 🏭 Masate: 39 years of excellence in sterile manufacturing, serving 43+ markets. Experts in lyophilisation and sterile liquid filling. 🏭 Pianezza: Leaders in oral liquid production with extensive packaging options, analytical services, and QP release. Secure your spot now and discover how Recipharm can launch your product! See you in Milan! #Pharmaceuticals #Manufacturing #Recipharm #SterileManufacturing #OralLiquids #Lyophilisation #CPHI2024
-
Exciting opportunity alert! 🚀 We're looking for a dynamic VP of Commercial to lead ReciBiopharm's growth and client success. Join a company that values innovation, collaboration, and work-life balance. Ready to drive our commercial strategy and join a global leader in CDMO? Apply now! https://lnkd.in/dVQy3i_P #Leadership #Biopharma #JobOpportunity
-
🧬The RNA therapeutics landscape is rapidly evolving, and manufacturers are under pressure to keep up. In a recent interview 🎙️, ReciBioPharm leaders Daniel Spurgin, Director of Strategic Partnerships, and Aaron B Cowley , Chief Scientific Officer at ReciBioPharm shared their vision for a more flexible, transparent and innovative future. Learn more in our insight article: https://lnkd.in/dZb_yTi4 #RNA #ContinuousManufacturing #CDMO
-
Delighted to share the latest insights from Jon Reed, our Head of Strategic Planning, on the groundbreaking potential of GLP-1 receptor agonists. These developments are set to revolutionise healthcare, extending far beyond diabetes management. Discover more by reading the full article here 👇
Unlocking the Future of Healthcare: The Transformative Power of GLP-1 Receptor Agonists GLP-1 receptor agonists are reshaping healthcare by expanding beyond type 2 diabetes management to treat obesity and cardiovascular disease. These groundbreaking drugs offer significant weight loss and improved health outcomes, redefining care standards for millions. In my latest article, I explore the exponential growth of GLP-1 drugs, the market forces propelling this advancement, and the vital role of Contract Development and Manufacturing Organizations (CDMOs) in meeting soaring demand. Read the full article to explore how GLP-1 receptor agonists are shaping the future of healthcare. #Pharmaceuticals #GLP1Agonists #Type2Diabetes #ObesityTreatment #CardiovascularHealth #HealthcareInnovation #DrugDevelopment #Biotech #CDMO #Recipharm #MedicalBreakthroughs #PharmaManufacturing #MarketGrowth #HealthcareIndustry #Therapeutics #PharmaTrends #DiabetesCare #ObesityAwareness #PharmaInvestments Recipharm
-
WHITE PAPER | On its mission to enhance its potentially life-changing therapy for frontotemporal dementia, our customer was faced with a challenge – to precisely measure a trace element crucial for the efficacy of its extended-release product. This element lacked the inherent characteristics required for standard quantification, placing an obstacle in the way of achieving accurate results and extending its journey to patients. In our white paper, we share the specialised approach and intricate processes we used to develop a robust analytical method to accurately detect and quantify trace elements that would help streamline the product’s release into the market. Read more: https://lnkd.in/dpsUbCHu #DrugDevelopment #ProcessDevelopment #DrugFormulation #OSDFormulation
-
Liknande sidor
Finansiering
Senaste finansieringsrunda
Aktiekapital efter börsintroduktion32 000 000,00 US$